(R)​-​CR8

SKU: orb1309189

Description

(R)​-​CR8

Research Area

Cell Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 294646-77-8
• MW: 431.53
• Purity: 98.41%
• Formula: C₂₄H₂₉N₇O
• SMILES: CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1
• Target: Apoptosis,CDK,Molecular Glues
• Solubility: DMSO:11 mg/mL (25.49 mM)

Bioactivity

• Target IC50:
  CDK1-CyclinB:0.09 μM|CDK9-CyclinT:0.18 μM|CK1δ/ε:0.4 μM|CDK2-CyclinA:0.072 μM|CDK7-CyclinH:1.1 μM|CDK5-p25:0.11 μM|CDK2-CyclinE:0.041 μM
• In Vivo:
  A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor--reduced CCA; cortical, hippocampal, and thalamic neuronal loss; and cortical microglial and astrocyte activation. furthermore , CR8 treatment attenuated sensorimotor and cognitive deficits, alleviated depressive-like symptoms, and decreased lesion volum.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Isomer, lesion, Hippocampus, death, CK1δ/ε, cdk2/cyclin A, CDK2/cyclinE, Cdk1/cyclin B, CDK, CDK9/Cyclin T, Cdk5/p25, CDK7/cyclin H, cell, CR 8, CR8, CR-8, CR8, (R)-Isomer, Apoptosis, caspases, (R)-Isomer, (R)​ ​CR8, (R)​​CR8, (R)​-​CR-8, (R)?-?CR8

Compound Identifiers

PubChem CID

10224714